Headlines about Charles River Laboratories Intl. (NYSE:CRL) have been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. AlphaOne, a service of Accern, scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Charles River Laboratories Intl. earned a media sentiment score of 0.17 on AlphaOne’s scale. AlphaOne also gave news articles about the company an impact score of 38 out of 100, indicating that recent media coverage is unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have impacted Alpha One Sentiment’s analysis:
- Zacks: Analysts Expect Charles River Laboratories Intl. Inc (CRL) Will Announce Earnings of $1.14 Per Share (americanbankingnews.com)
- Charles River Laboratories Schedules First-Quarter 2017 Earnings Release and Conference Call (finance.yahoo.com)
- Charles River Laboratories International, Inc. – Value Analysis (NYSE:CRL) : April 12, 2017 (finance.yahoo.com)
- Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish Manner : CRL-US : April 11, 2017 (finance.yahoo.com)
- Charles River Laboratories International, Inc. (NYSE:CRL): Technical Valuation Breakdown – TCT (twincitytelegraph.com)
Several research firms recently commented on CRL. Jefferies Group LLC restated a “buy” rating on shares of Charles River Laboratories Intl. in a research report on Thursday, March 16th. Evercore ISI upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $86.50 price objective for the company in a report on Wednesday, January 4th. Finally, Goldman Sachs Group Inc upgraded Charles River Laboratories Intl. from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $75.00 to $77.00 in a report on Friday, December 16th. They noted that the move was a valuation call. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $85.95.
Charles River Laboratories Intl. (NYSE:CRL) traded up 0.33% during trading on Thursday, hitting $87.38. The stock had a trading volume of 232,198 shares. Charles River Laboratories Intl. has a 52-week low of $67.20 and a 52-week high of $91.57. The firm has a market cap of $4.14 billion, a P/E ratio of 27.09 and a beta of 0.99. The company has a 50-day moving average of $88.51 and a 200 day moving average of $80.93.
Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Tuesday, February 14th. The company reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.10. Charles River Laboratories Intl. had a return on equity of 25.75% and a net margin of 9.05%. The company had revenue of $466.80 million for the quarter, compared to analysts’ expectations of $441.64 million. During the same period last year, the firm earned $1.00 EPS. Charles River Laboratories Intl.’s revenue for the quarter was up 31.9% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories Intl. will post $5.06 earnings per share for the current fiscal year.
In related news, insider Davide Molho sold 11,717 shares of the firm’s stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $90.00, for a total value of $1,054,530.00. Following the transaction, the insider now directly owns 28,266 shares of the company’s stock, valued at approximately $2,543,940. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David P. Johst sold 13,950 shares of the firm’s stock in a transaction on Monday, January 30th. The stock was sold at an average price of $78.00, for a total value of $1,088,100.00. Following the completion of the transaction, the insider now directly owns 174,696 shares in the company, valued at $13,626,288. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,932 shares of company stock worth $7,472,459. 2.30% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This piece was first published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at http://sleekmoney.com/charles-river-laboratories-intl-crl-getting-somewhat-positive-news-coverage-study-shows/1739562.html.
Charles River Laboratories Intl. Company Profile
Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/charles-river-laboratories-intl-crl-getting-somewhat-positive-news-coverage-study-shows/1739562.html
Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.